Saturday, May 7, 2022 1:45 PM – 2:30 PM ET Exhibit Hall, Workshop Room 1
Exhibitor Workshop: BioLegend
Inactivation of SARS-COV2 for Analysis of Samples Using LEGENDplex Multiple Assays and Flow Cytometry
- Theodore G Liou, M.D., Prof. of Internal Med., Univ. of Utah
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a life-threatening pathogen that requires extreme caution when handling samples with active viral particles. The CDC recommends that processing of samples containing SARS-CoV-2 should be performed in biosafety level 3 laboratories. This restricts many research groups without access to biosafety 3 laboratories from safely analyzing samples. Herein, we present a strategy for rendering SARS-CoV-2 inactive in samples for bead-based immunoassays (LEGENDplex analysis) and flow cytometry, which allows sample characterization at reduced biosafety levels. The strategy may facilitate the analysis of samples potentially containing other viral pathogens after sufficient additional safety testing.
Theodore G Liou collaborates with Biolegend and received reagents for the performance of this work. Dr. Liou is a Tenured Faculty Member of the University of Utah and is the Director of the Adult CF Care Center and member of the Center for Quantitative Biology at the U of Utah. He is supported by grant funding from the NHLBI (R01 HL125520), the US CF Foundation (CC132-16AD, LIOU14Y0, LIOU14P0), the Margolis Family Foundation of Utah and the Claudia Ruth Goodrich Stevens Endowment Fund. Dr. Liou and the CF Center at the University of Utah received funding within the last three years to perform sponsored clinical trials focused on CF from Abbvie, Aridis, Armata, BiomX, Calithera Biosciences, Corbus Pharmaceuticals, Gilead Sciences, Laurent Pharmaceuticals, Nivalis Therapeutics, Novartis, Proteostasis, Savara Pharmaceuticals, Translate Bio and Vertex Pharmaceuticals. None of the commercial research sponsors were involved with the current presentation. Dr. Liou is a member of the Clinical Research Award Committee at the CF Foundation and is a member of the Steering Committee for the CF Foundation’s Therapeutic Development Network.